Manhua Ding1, Liang Liu1, Chengxi Hu1, Yi Liu1, Yun Qiao1, Xiaodong Jiang1. 1. 1 Xuzhou Medical College, Xuzhou 221006, China ; 2 Department of Oncology, Xuzhou Cancer Hospital, Xuzhou 221005, China ; 3 Department of Radiotherapy Oncology, Lianyungang First People's Hospital, Lianyungang 222002, China.
Abstract
OBJECTIVE: Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2 (VEGFR2) and neuropilin-1 (NRP-1) can be biomarkers for clinical treatment. We aimed to investigate the expression levels of VEGFR2 and NRP-1 in human non-small cell lung cancer (NSCLC) and their clinical significance by observing patient prognosis. METHODS: VEGFR2 and NRP-1 were assessed by immunohistochemistry (IHC) in 40 patients with NSCLC and in 10 patients with benign lesions of lung; kinase insert domain receptor (KDR) and NRP-1 copy number gain (CNG) was assessed by fluorescence in situ hybridization (FISH). The distributions of overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared between groups by log-rank test. RESULTS: Rates of positive immunostaining for VEGFR2 and NRP-1 were 58% and 55%, respectively. KDR and NRP-1 CNG (+) were detected in 32.5% and 30% of tumors, respectively. Levels of both VEGFR2 and NRP-1 in lung tumors were significantly different than in the control tissue (χ(2)=11.22, P=0.001; χ(2)=9.82, P=0.001, respectively); similar results were obtained using CNGs (χ(2)=4.39, P=0.036; χ(2)=3.95, P=0.046, respectively). Statistically significant correlations were observed with histological grade, clinical TNM stage and the lymph node status (P<0.05), but not age, gender or pathology type (P>0.05). VEGFR2 showed a strong correlation with NRP-1 (Rs=0.68, P=0.00); similar results were observed with KDR and NRP-1 CNG (Rs=0.32, P=0.04). Significant differences in OS and PFS were observed between the groups with higher VEGFR2 and NRP-1 and those with lower expression (P<0.05). CONCLUSIONS: According to these data, VEGFR2 and NRP-1 are highly expressed in NSCLC. We can conclude that they play a key role in NSCLC occurrence, development and metastasis and are associated with patient prognosis (P<0.05 for OS and PFS). This information will be beneficial for clinical anti-angiogenic treatment in NSCLC.
OBJECTIVE: Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2 (VEGFR2) and neuropilin-1 (NRP-1) can be biomarkers for clinical treatment. We aimed to investigate the expression levels of VEGFR2 and NRP-1 in humannon-small cell lung cancer (NSCLC) and their clinical significance by observing patient prognosis. METHODS:VEGFR2 and NRP-1 were assessed by immunohistochemistry (IHC) in 40 patients with NSCLC and in 10 patients with benign lesions of lung; kinase insert domain receptor (KDR) and NRP-1copy number gain (CNG) was assessed by fluorescence in situ hybridization (FISH). The distributions of overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared between groups by log-rank test. RESULTS: Rates of positive immunostaining for VEGFR2 and NRP-1 were 58% and 55%, respectively. KDR and NRP-1 CNG (+) were detected in 32.5% and 30% of tumors, respectively. Levels of both VEGFR2 and NRP-1 in lung tumors were significantly different than in the control tissue (χ(2)=11.22, P=0.001; χ(2)=9.82, P=0.001, respectively); similar results were obtained using CNGs (χ(2)=4.39, P=0.036; χ(2)=3.95, P=0.046, respectively). Statistically significant correlations were observed with histological grade, clinical TNM stage and the lymph node status (P<0.05), but not age, gender or pathology type (P>0.05). VEGFR2 showed a strong correlation with NRP-1 (Rs=0.68, P=0.00); similar results were observed with KDR and NRP-1 CNG (Rs=0.32, P=0.04). Significant differences in OS and PFS were observed between the groups with higher VEGFR2 and NRP-1 and those with lower expression (P<0.05). CONCLUSIONS: According to these data, VEGFR2 and NRP-1 are highly expressed in NSCLC. We can conclude that they play a key role in NSCLC occurrence, development and metastasis and are associated with patient prognosis (P<0.05 for OS and PFS). This information will be beneficial for clinical anti-angiogenic treatment in NSCLC.
Entities:
Keywords:
Non-small cell lung cancer (NSCLC); fluorescence in situ hybridization (FISH); neuropilin-1 (NRP-1); vascular endothelial growth factor receptor 2 (VEGFR2)
Authors: Fei Yang; Ximing Tang; Erick Riquelme; Carmen Behrens; Monique B Nilsson; Uma Giri; Marileila Varella-Garcia; Lauren A Byers; Heather Y Lin; Jing Wang; Maria G Raso; Luc Girard; Kevin Coombes; J Jack Lee; Roy S Herbst; John D Minna; John V Heymach; Ignacio I Wistuba Journal: Cancer Res Date: 2011-07-01 Impact factor: 12.701
Authors: Ximing Tang; Humam Kadara; Carmen Behrens; Diane D Liu; Yun Xiao; David Rice; Adi F Gazdar; Junya Fujimoto; Cesar Moran; Marileila Varella-Garcia; J Jack Lee; Waun Ki Hong; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2011-01-21 Impact factor: 12.531
Authors: Anna Starzec; Roger Vassy; Antoine Martin; Marc Lecouvey; Mélanie Di Benedetto; Michel Crépin; Gérard Y Perret Journal: Life Sci Date: 2006-08-16 Impact factor: 5.037
Authors: Smita Mehta; James Moon; Mehmood Hashmi; Michael Leblanc; Chao Hui Huang; Elizabeth Rinehart; Gregory T Wolf; Susan G Urba; Sushanta K Banerjee; Stephen Williamson Journal: Oncol Rep Date: 2013-04-02 Impact factor: 3.906
Authors: Timothy R Holzer; Angie D Fulford; Drew M Nedderman; Tara S Umberger; Rebecca R Hozak; Adarsh Joshi; Symantha A Melemed; Laura E Benjamin; Gregory D Plowman; Andrew E Schade; Bradley L Ackermann; Robert J Konrad; Aejaz Nasir Journal: PLoS One Date: 2013-11-14 Impact factor: 3.240